Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

5.4K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
5.4K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

672
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
672
Coagulation01:09

Coagulation

6.1K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
6.1K
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

7.0K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
7.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

SmartAlert - Implementing Machine Learning-Driven Clinical Decision Support for Inpatient Laboratory Utilization Reduction.

NEJM AI·2026
Same author

CEACAM1 expression by immunohistochemistry in B-cell lymphomas and plasma cell myeloma.

American journal of clinical pathology·2026
Same author

Clinical significance of anti-M in pregnancy and self-reported ancestry: The BEST collaborative study.

Transfusion·2026
Same author

Pregnancy in the Workplace: Addressing Gaps in Reproductive Health-Specific Occupational Guidelines.

Journal of occupational and environmental medicine·2026
Same author

Electronic enhancement to decrease rejection of blood type verification specimens.

Transfusion·2025
Same author

Implementation of pathogen reduced cryoprecipitate for surgical services: A retrospective review of blood product utilization and fibrinogen repletion.

Transfusion·2025

Related Experiment Video

Updated: Jun 22, 2025

Characterization of Leukocyte-platelet Rich Fibrin, A Novel Biomaterial
08:14

Characterization of Leukocyte-platelet Rich Fibrin, A Novel Biomaterial

Published on: September 29, 2015

12.9K

Implementation and early outcomes with Pathogen Reduced Cryoprecipitated Fibrinogen Complex.

V Rakesh Sethapati1, Tho D Pham2, Thinh Quach3

  • 1Department of Pathology, University of Arkansas for Medical Sciences, Little Rock, AR, US.

American Journal of Clinical Pathology
|July 5, 2024
PubMed
Summary

Implementing Pathogen Reduced Cryoprecipitated Fibrinogen Complex (IFC) significantly reduced waste and turnaround time for fibrinogen replacement. This improves blood bank logistics and patient care efficiency.

Keywords:
Pathogen Reduced Cryoprecipitated Fibrinogen Complexcryoprecipitatetransfusion medicine

More Related Videos

Leveraging Turbidity and Thromboelastography for Complementary Clot Characterization
06:28

Leveraging Turbidity and Thromboelastography for Complementary Clot Characterization

Published on: June 4, 2020

6.8K
Author Spotlight: Advancing Thrombolytic Testing by Integrating Flow Dynamics in In Vitro Models
06:16

Author Spotlight: Advancing Thrombolytic Testing by Integrating Flow Dynamics in In Vitro Models

Published on: April 19, 2024

936

Related Experiment Videos

Last Updated: Jun 22, 2025

Characterization of Leukocyte-platelet Rich Fibrin, A Novel Biomaterial
08:14

Characterization of Leukocyte-platelet Rich Fibrin, A Novel Biomaterial

Published on: September 29, 2015

12.9K
Leveraging Turbidity and Thromboelastography for Complementary Clot Characterization
06:28

Leveraging Turbidity and Thromboelastography for Complementary Clot Characterization

Published on: June 4, 2020

6.8K
Author Spotlight: Advancing Thrombolytic Testing by Integrating Flow Dynamics in In Vitro Models
06:16

Author Spotlight: Advancing Thrombolytic Testing by Integrating Flow Dynamics in In Vitro Models

Published on: April 19, 2024

936

Area of Science:

  • Transfusion Medicine
  • Hematology
  • Blood Banking

Background:

  • Cryoprecipitated antihemophilic factor (cryo) is vital for fibrinogen replacement but has limitations including a short shelf-life (4-6 hours post-thaw) and long issuance times.
  • These limitations hinder its effective use in actively bleeding patients, dysfibrinogenemia, and hypofibrinogenemia.

Purpose of the Study:

  • To evaluate the impact of implementing Pathogen Reduced Cryoprecipitated Fibrinogen Complex (INTERCEPT Fibrinogen Complex [IFC]) on cryoprecipitate waste and turnaround time.
  • To assess improvements in blood bank logistics and patient care efficiency.

Main Methods:

  • Identified high-utilization and high-waste locations for cryoprecipitate.
  • Partnered with a blood supplier to introduce IFC in targeted locations, replacing cryoprecipitate orders.
  • Analyzed waste rates and turnaround times before and after IFC implementation.

Main Results:

  • Waste rates in targeted operative locations decreased from 16.7% to 2.2% after IFC implementation.
  • Overall waste of cryoprecipitated products across all locations reduced from 8.8% to 2.4%.
  • Turnaround time for cryoprecipitated products decreased by 58%, from 30.4 minutes to 14.6 minutes.

Conclusions:

  • Implementation of IFC led to substantial reductions in waste and improved turnaround times.
  • These changes enhanced blood bank logistics, streamlined patient care, and minimized costly product wastage.